000136676 001__ 136676
000136676 005__ 20240229105054.0
000136676 0247_ $$2doi$$a10.1158/1055-9965.EPI-17-0744
000136676 0247_ $$2pmid$$apmid:29661801
000136676 0247_ $$2ISSN$$a1055-9965
000136676 0247_ $$2ISSN$$a1538-7755
000136676 0247_ $$2altmetric$$aaltmetric:38154307
000136676 037__ $$aDKFZ-2018-01144
000136676 041__ $$aeng
000136676 082__ $$a610
000136676 1001_ $$aCramer, Daniel W$$b0
000136676 245__ $$aAnti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
000136676 260__ $$aPhiladelphia, Pa.$$bAACR$$c2018
000136676 3367_ $$2DRIVER$$aarticle
000136676 3367_ $$2DataCite$$aOutput Types/Journal article
000136676 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536310159_16664
000136676 3367_ $$2BibTeX$$aARTICLE
000136676 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136676 3367_ $$00$$2EndNote$$aJournal Article
000136676 520__ $$aBackground: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined.Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression.Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both.Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types.Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC. Cancer Epidemiol Biomarkers Prev; 27(7); 790-804. ©2018 AACR.
000136676 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136676 588__ $$aDataset connected to CrossRef, PubMed,
000136676 7001_ $$aFichorova, Raina N$$b1
000136676 7001_ $$aTerry, Kathryn L$$b2
000136676 7001_ $$aYamamoto, Hidemi$$b3
000136676 7001_ $$aVitonis, Allison F$$b4
000136676 7001_ $$aArdanaz, Eva$$b5
000136676 7001_ $$aAune, Dagfinn$$b6
000136676 7001_ $$aBoeing, Heiner$$b7
000136676 7001_ $$aBrändstedt, Jenny$$b8
000136676 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b9
000136676 7001_ $$aChirlaque, Maria-Dolores$$b10
000136676 7001_ $$aDorronsoro, Miren$$b11
000136676 7001_ $$aDossus, Laure$$b12
000136676 7001_ $$aDuell, Eric J$$b13
000136676 7001_ $$aGram, Inger T$$b14
000136676 7001_ $$aGunter, Marc$$b15
000136676 7001_ $$aHansen, Louise$$b16
000136676 7001_ $$aIdahl, Annika$$b17
000136676 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron Scot$$b18$$udkfz
000136676 7001_ $$aKhaw, Kay-Tee$$b19
000136676 7001_ $$aKrogh, Vittorio$$b20
000136676 7001_ $$aKvaskoff, Marina$$b21
000136676 7001_ $$aMattiello, Amalia$$b22
000136676 7001_ $$aMatullo, Giuseppe$$b23
000136676 7001_ $$aMerritt, Melissa A$$b24
000136676 7001_ $$aNodin, Björn$$b25
000136676 7001_ $$aOrfanos, Philippos$$b26
000136676 7001_ $$aOnland-Moret, N Charlotte$$b27
000136676 7001_ $$aPalli, Domenico$$b28
000136676 7001_ $$aPeppa, Eleni$$b29
000136676 7001_ $$aQuirós, J Ramón$$b30
000136676 7001_ $$aSánchez-Perez, Maria-Jose$$b31
000136676 7001_ $$aSeveri, Gianluca$$b32
000136676 7001_ $$aTjønneland, Anne$$b33
000136676 7001_ $$aTravis, Ruth C$$b34
000136676 7001_ $$aTrichopoulou, Antonia$$b35
000136676 7001_ $$aTumino, Rosario$$b36
000136676 7001_ $$aWeiderpass, Elisabete$$b37
000136676 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b38$$udkfz
000136676 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b39$$eLast author$$udkfz
000136676 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-17-0744$$gVol. 27, no. 7, p. 790 - 804$$n7$$p790 - 804$$tCancer epidemiology, biomarkers & prevention$$v27$$x1538-7755$$y2018
000136676 909CO $$ooai:inrepo02.dkfz.de:136676$$pVDB
000136676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000136676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b38$$kDKFZ
000136676 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b39$$kDKFZ
000136676 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136676 9141_ $$y2018
000136676 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2015
000136676 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136676 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136676 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136676 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136676 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136676 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136676 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136676 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136676 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136676 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136676 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136676 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000136676 980__ $$ajournal
000136676 980__ $$aVDB
000136676 980__ $$aI:(DE-He78)C020-20160331
000136676 980__ $$aUNRESTRICTED